Detalles de la búsqueda
1.
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Ann Oncol
; 31(1): 72-78, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31912799
2.
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Ann Oncol
; 30(11): 1796-1803, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31868905
3.
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
BMC Cancer
; 19(1): 990, 2019 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31646981
4.
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
Int J Cancer
; 138(3): 739-46, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26284333
5.
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Ann Oncol
; 27(8): 1565-72, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27234640
6.
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
ESMO Open
; 9(5): 103374, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38744100
7.
Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
Br J Cancer
; 109(6): 1428-36, 2013 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23963138
8.
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Br J Cancer
; 108(2): 469-76, 2013 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23169292
9.
Resilience in cancer patients and how it correlates with demographics, psychological factors, and lifestyle.
J Cancer Res Clin Oncol
; 149(8): 5279-5287, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36396875
10.
Sense of coherence and its context with demographics, psychological aspects, lifestyle, complementary and alternative medicine and lay aetiology.
J Cancer Res Clin Oncol
; 149(11): 8393-8402, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37079052
11.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Ann Oncol
; 23(7): 1693-9, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22219013
12.
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Br J Cancer
; 105(2): 206-11, 2011 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-21750558
13.
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Ann Oncol
; 22(8): 1798-804, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21266516
14.
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
Eur J Cancer
; 146: 95-106, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33588150
15.
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Eur J Cancer
; 106: 115-125, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30496943
16.
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Eur J Cancer
; 94: 95-103, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29549862
17.
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Eur J Cancer
; 84: 262-269, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28843184
18.
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Eur J Cancer
; 79: 50-60, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28463756
19.
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Ann Oncol
; 17(4): 663-7, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16423848
Resultados
1 -
19
de 19
1
Próxima >
>>